- Phoenix and Raven have become the first telehealth platforms in Canada to launch direct-to-patient access to generic Semaglutide, with prescriptions starting at $124.99 and delivery available nationwide
- The launch follows Health Canada’s April 2026 approval of generic semaglutide, making Canada the first G7 country to authorize the medication and opening the door for broader affordability and access
- Phoenix and Raven said demand ahead of launch was strong, with thousands of Canadians joining waitlists as interest in GLP-1 therapies for chronic disease and weight management continues to grow across the country
- The companies noted that the generic semaglutide supplied through their platforms is sourced and distributed domestically, while eligibility for treatment remains subject to assessment by licensed Canadian healthcare providers
Takeaways
Phoenix and Raven are turning Canada’s new generic semaglutide approvals into immediate, retail-like access, which will likely accelerate GLP‑1 uptake beyond traditional brick‑and‑mortar clinics.
By offering domestically sourced generic semaglutide from about $125 with nationwide delivery and strong pre‑launch waitlist demand, these platforms are set to pull more diabetes and weight‑management patients into telehealth, pressure pricing for in‑person providers, and force payers and regulators to pay closer attention to how GLP‑1s are used and monitored in largely virtual care models.
Source: Businesswire
